ASCO GU 2023 Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial: Evaluating Cabozantinib + Nivo & Ipi in 1L Advanced RCC of IMDC Intermediate or Poor Risk

205 views
March 1, 2023
1 Comment
Login to view comments. Click here to Login